Best Vaccine Stocks

Major vaccine companies such as Eli Lilly, Pfizer, and AstraZeneca may not be in the news as much since the height of the COVID-19 pandemic, but there are signs that interest in them could rise again. With the possibility of a second Trump administration, investors are paying attention to the nomination of Robert F. Kennedy Jr., who is known for his critical views on vaccines.

Pfizer (PFE 0.23%) has been struggling recently, despite reporting some good earnings. Investors are worried about significant challenges that could decrease its $145 billion value in the future.

AstraZeneca's blockbuster breast cancer drug will be added to China's national reimbursement scheme list, according to an update from the National Healthcare Security Administration.

AstraZeneca's Fasenra, an injectable treatment for severe asthma, is more effective during attacks than the oral steroid that has been the standard of care for 50 years, cutting the need for further treatment by 30%, according to a study published on Wednesday.

NEW YORK, NY / ACCESSWIRE / November 27, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Novavax, Inc. ("Novavax" or the "Company") (NASDAQ:NVAX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

The average of price targets set by Wall Street analysts indicates a potential upside of 93.5% in Dynavax Technologies (DVAX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

MALVERN, Pa., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen will present at NobleCon20 – Noble Capital Markets' 20th Annual Emerging Growth Equity Conference at Florida Atlantic University, Executive Education Complex, in Boca Raton, FL—taking place December 3 - 4, 2024.

A selection of strong dividend-growth stocks that are close to their 52-week lows is analyzed using past and expected fair values. Pfizer's financial situation raises some worries due to its high dividend payout ratios and negative debt-to-equity ratios, but forecasts indicate a chance for improvement. Even with political risks and worries from activist investors, PFE's attractive initial dividend yield, good ratings, and encouraging product pipeline could mean it is undervalued.

While no one can foresee what will happen in the future, it's easy to picture a rise in pharmaceutical sales. In 2022, spending on prescription drugs in the U.S. grew by over 8%, totaling $406 billion.